

03 February 2009



**National Institute for
Health and Clinical Excellence**

Midcity Place
71 High Holborn
London
WC1V 6NA

Tel: 020 7067 5800
Fax: 020 7067 5801

www.nice.org.uk

Dear Consultee/Commentator

**Health Technology Appraisal: Bevacizumab, sorafenib, sunitinib and
temsirolimus for the treatment of advanced and/or metastatic renal cell
carcinoma**

As I know you are aware, there has been unprecedented public interest in this technology appraisal and in our evaluation, and in that context, I have been considering how best to manage the publication of the outcome of the Appraisal Committee meeting held on 14th of January.

We would normally give consultees and commentators 5 working days notice of publication of a FAD or and ACD. However, because of the considerable public interest in this appraisal over an extended period and because I have reason to believe that the content of an earlier consultation document was leaked, I am not confident that the confidentiality of the documents we intend to publish now, can be maintained. I have therefore decided that the documents will be published tomorrow morning, Wednesday 4 February. Copies of what is to be published tomorrow are enclosed with this letter.

This decision does not affect the standard time periods available for appeal against the FAD or to comment on the ACD.

Yours sincerely,

Andrew Dillon
Chief Executive